Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Nuclear Medicine and Molecular Imaging
Published in: Nuclear Medicine and Molecular Imaging 1/2019

01-02-2019 | Radionuclide Therapy | Perspective

Nuclear Medicine Theranostics: Perspective from Pakistan

Authors: Humayun Bashir, M. Numair Younis, M. Rehan Gul

Published in: Nuclear Medicine and Molecular Imaging | Issue 1/2019

Login to get access

Abstract

Nuclear medicine has been offering diagnostic and therapeutic solution since the introduction of radioactive iodine for thyroid diseases since decades. However, the concept of theranostics has given a new found impetus to the use of pairs of radiopharmaceuticals for diagnosis and treatment. Presented here is a perspective on theranostics from Pakistan.
Literature
1.
Younis N, Bashir H. Theranostics–neuroendocrine tumours. J Cancer Allied Spec. 2018;4(2):1.
2.
Sawin CT, Becker DV. Radioiodine and the treatment of hyperthyroidism: the early history. Thyroid. 1997;7:163–76.CrossRefPubMed
3.
Sharp SE, Trout AT, Weiss BD, Gelfand MJ. MIBG in neuroblastoma diagnostic imaging and therapy. Radiographics. 2016;36:258–78.CrossRefPubMed
4.
Ahmadzahehfar H, Sabet A, Wilhelm K, Biersack HJ. Iodine-131-lipiodol therapy in hepatic tumours. Methods. 2011;55:246–52.CrossRef
5.
Rizzieri D. Z. (ibritumomabtiuxetan) after more than a decade of treatment experience, what have we learned. Crit Rev OncolHematol. 2016;105:5–17.CrossRef
6.
Handkiewicz-Junak D, Poeppel TD, Bodei L, Aktolun C, Ezziddin S, Giammarile F, et al. EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides. Eur J Nucl Med Mol Imaging. 2018;45:846–59.CrossRefPubMedPubMedCentral
7.
Kunikowska J, Lewington V, Krolicki L. Optimizing somatostatin receptor imaging in patients with neuroendocrine tumors: the impact of 99mTc-HYNICTOC SPECT/SPECT/CT versus 68Ga-DOTATATE PET/CT upon clinical management. Clin Nucl Med. 2017;42:905–11.CrossRefPubMed
8.
Ajit S. Rhenium 188: the poor Man’s yttrium. World J Nucl Med. 2017;16:1–2.CrossRef
9.
Zaman MU, Fatima N, Sajjad Z, Hashmi I. High-dose I131 therapy on outpatient basis: imperative and no more a desire. Pak J Nucl Med. 2012;2:92–7.
10.
Memon AS, Laghari NA, Mangi FH, Hussain MM, Nohario SH. Isolation period of 131I administered patients at NIMRA Jamshoro Pakistan. Int J Radiol Radiat Ther. 2017;2:2–5.
11.
Hassan A, Siddique M, Bashir H, Riaz S, Wali R, Mahreen A, et al. 18F-FDG PET-CT imaging versus bone marrow biopsy in pediatric Hodgkin’s lymphoma: a quantitative assessment of marrow uptake and novel insights into clinical implications of marrow involvement. Eur J Nucl Med Mol Imaging. 2017;44:1198–206.CrossRefPubMed
12.
Riaz S, Bashir H, Niazi IK. Triage of limited versus extensive disease on F18 FDG PET/CT scan in small cell lung cancer Asia Ocean. J Nucl Med Biol. 2017;5:109–13.
13.
Riaz S, Bashir H, Hassan L, Jamshed A, Murtaza A, Hussain R. Impact and prognostic value of 18F FDG PET-CT scan in the evaluation of residual head and neck cancer - single centre experience from Pakistan. South Asian J Cancer. 2017;6:81–3.PubMedPubMedCentral
14.
Zaman MU, Fatima N, Zaman A, et al. Significantly low effective dose from 18FDG PET/CT scans using dose reducing strategies: “lesser is better”. Asian Pac J Cancer Prev. 2016;17:3465–8.PubMed
15.
Riaz S, Nawaz MK, Faruqui ZS, Kazmi AS, Loya A, et al. Diagnostic accuracy of 18F-FDG PET-CT in the evaluation of carcinoma of unknown primary. Mol Imaging Radionucl Ther. 2016;25:1–10.CrossRef
16.
Bodei L, Brand MJ, Baum RP, Pavel ME, Horsch D, O’Dorisio MS, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40:800–16.CrossRefPubMedPubMedCentral
17.
Strosberg J, El-Haddad G, Wolin E, Hendifar A, Chasen B, Mittra E, et al. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125–35.CrossRefPubMedPubMedCentral
18.
Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, et al. Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with 177Lu-dotatate in the phase III NETTER-1 trial. J Clin Oncol. 2018;36:2578–84.CrossRefPubMedPubMedCentral
19.
Mittra ES. Neuroendocrine tumor therapy: 177Lu-DOTATATE. Am J Roentgenol. 2018;211:278–85.CrossRef
20.
Virgolini I, Decristoforo C, Haug A, Fanti S, Uprimny C. Current status of theranostics in prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45:471–95.CrossRefPubMed
21.
Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, et al. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19:825–33.CrossRefPubMed
22.
23.
Ajit S. An overview of nuclear medicine and PET CT in India. Curr Trends Clin Med Imaging. 2017;1(5).
24.
Atutornu J, Hayre CM. Personalized medicine and medical imaging: opportunities and challenges for contemporary health care. J Med Imaging Radiat Sci. 2018;49:352–9.CrossRefPubMed
Metadata
Title
Nuclear Medicine Theranostics: Perspective from Pakistan
Authors
Humayun Bashir
M. Numair Younis
M. Rehan Gul
Publication date
01-02-2019
Publisher
Springer Berlin Heidelberg
Published in
Nuclear Medicine and Molecular Imaging / Issue 1/2019
Print ISSN: 1869-3474
Electronic ISSN: 1869-3482
DOI
https://doi.org/10.1007/s13139-018-00566-7

Other articles of this Issue 1/2019

Nuclear Medicine and Molecular Imaging 1/2019 Go to the issue

Perspective

Activities for the Development of Targeted Radionuclide Therapy in Japan

Review

Radiomics in Oncological PET/CT: a Methodological Overview

Original Article

Diagnostic Reference Levels for Adult Nuclear Medicine Imaging Established from the National Survey in Korea

Correction

Correction to: Bone Scintigraphy and Tenofovir-Induced Osteomalacia in Chronic Hepatitis B

Perspective

Nuclear Theranostics in Indonesia: Past, Present, and Future

Perspective

Dawn of Theranostics in Myanmar (Dream, Reality, and Constraint)